Kezar Life Sciences, Inc. (KZR) Asset Writedowns and Impairment (2023 - 2026)

Kezar Life Sciences has reported Asset Writedowns and Impairment for 4 years, with the latest figure at $119000.0 in Q1 2026.

• Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $119000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (down 61.3% YoY) and the FY2025 annual result came in at $907000.0, changed N/A from the prior year.
• Asset Writedowns and Impairment slipped to $119000.0 in Q1 2026 per KZR's latest filing, from $907000.0 in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $2.7 million in Q4 2023 and troughed at -$1.5 million in Q4 2024.
• A 4-year average of $735400.0 and a median of $907000.0 in 2025 frame the typical range for Asset Writedowns and Impairment.
• The sharpest annual moves came in 2024 and 2025: Asset Writedowns and Impairment tumbled 157.37% in 2024, then surged 158.55% in 2025.
• Over 4 years, Asset Writedowns and Impairment stood at $2.7 million in 2023, then slumped by 157.37% to -$1.5 million in 2024, then soared by 158.55% to $907000.0 in 2025, then tumbled by 86.88% to $119000.0 in 2026.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $119000.0, $907000.0, and -$1.5 million for Q1 2026, Q4 2025, and Q4 2024 respectively.